We are working to develop new breakthrough drugs against diseases for which there are no appropriate therapeutic drugs. To maximize the speed at which we can launch our products on the market, we focus on exploratory research and fundamentally conduct venture-based drug discovery research, which involves out-licensing, at an early stage, the development of compounds we have discovered to highly specialized companies in Japan and abroad. Aiming to implement AI-based drug development and other new techniques, we are tackling drug development themes that might lead to innovative new drugs, while focusing primarily on hyperuricemia, pain, and other areas in which we have extensive track records.

NC-2600 / P2X4 receptor antagonist (for neuropathic pain)

Patients with neuropathic pain are forced to have a hard time suffering from severe pain based on various neurological disorders. However, since there are few viable treatment options in terms if remedies, a new treatment needs to be developed.
In joint research with Kyushu University, we have developed a new formulation to treat neuropathic pain. Since FY2012, the Company has been carrying out research with the support of AMED and, during FY2014, discovered NC-2600. This is a development candidate, which appears to be potentially effective through oral administration. In FY2017, we completed phase 1 testing. We are currently conducting licensing out activities of aimed at domestic and international companies.
We will explore NC-2600’s potential as a first-in-class drug, primarily by examining possible new indications for the compound as a treatment for conditions other than neuropathic pain. At the same time, we will create further licensing-out opportunities, thereby increasing the compound’s value.

NC-2800 / δ opioid receptor agonist (for depression, anxiety)

NC-2800 is a chemical compound with strong potential as an anti-depression and anti-anxiety treatment that the Company discovered through collaborative study with the University of Tsukuba, Kitasato University, and the National Center of Neurology and Psychiatry.
The compound was selected by AMED’s industry–academia collaboration program (ACT-M) in 2015 and, while receiving the agency’s support, we conducted preclinical trials. As a result, the compound received high acclaim for its potential as a therapeutic drug candidate.
In 2018, AMED’s CiCLE project* selected it for public funding and support. In anticipation of phase 1 testing set to begin in 2021, we are currently manufacturing active pharmaceutical ingredients and manufacturing pharmaceutical products associated with the compound, in accordance with good manufacturing practices, while receiving support from AMED. At the same time, we are out-licensing the compound to companies in Japan and abroad.

* Theme of R&D: Development of a breakthrough emotion-regulating agent with a mechanism for activating δ opioid receptors; AMED will provide support from March 30, 2018 until March 31, 2027.

NC-2500 / XOR inhibitor (for gout, hyperuricemia)

NC-2500 is a novel advanced xanthine oxidoreductase (XOR) inhibitor, having potential to reduce the risk of gout flare, one of major issues of current treatments for gout, and make a difference in gout treatment.
In the Phase-1 study, NC-2500 showed favorable urate-lowering properties, that is NC-2500 lowered serum urate levels gradually to the same extent as current XOR inhibitors through 7 days, which could decrease the risk of acute flare in gout patients. Acute flare due to rapid urate reduction is one of the major issues in the initial phase of current therapy, which impairs patients’ quality of life and adherence, frequently resulting in failing sufficient control of serum urate and then worsening the disease. NC-2500 is expected to have potential to resolve these issues by its unique profile of reducing urate to avoid acute flare, with no need of or minimal titration. As for safety, NC-2500 was well-tolerated and adverse events were infrequent, transient, mild, and comparable to placebo. Furthermore, NC-2500 was hardly excreted through the renal pathway, which can be a favorite profile for patients with renal impairment, frequently observed in gout.

NC-2700 / URAT-1 inhibitor (for gout, hyperuricemia)

NC-2700 is a novel urate transporter 1 (URAT1) inhibitor, enhancing excretion urate to urine. NC-2700 showed not just a potent uricosuric effect, but also pH-raising of the urine with lowered pH in an animal model, which could decrease the risk of renal calculus and nephrotoxicity with urate crystal in the urine, the most common issue with current uricosuric therapy.

Business Development
We are interested in any opportunities of collaboration, partnering or licensing of our pipeline products and welcome any proposal on them.
If you have any interest in any of our pipeline products, please contact our business development team: bd@chemiphar.co.jp.
Related Information

Business Development Contact

If you have any interest in our pipeline, please contact our business development team bd@chemiphar.co.jp.

Get ADOBE® READER®

NOTICE
To view our PDF files, you need Adobe Reader software installed on your local drive. The Adobe Reader can be downloaded by clicking on this icon.

PageTop